Its lead programme uses a sortilin inhibitor to rebalance levels of progranulin in patients where the sortilin receptor would otherwise reduce circulating and extracellular progranulin, contributing to disease. Progranulin is a protein that the body uses to regulate cell growth, survival, repair and avoid inflammation. Low progranulin levels are believed to be a factor in cell dysfunction and damage in a range of indications across neurology. By normalizing progranulin levels, Vesper believes its compounds will have a disease modifying effect, protecting and preserving the remaining cells.

Recent Milestones: first in human dosing and proof of target engagement 

Upcoming Milestones: clinical proof of principle, phase Ib FPFV in GRN +/- carriers Products: VES001 the first oral, brain penetrant sortilin inhibitor for treatment of FTD(GRN) 

Investors: Lundbeckfonden BioCapital 

Full Company address & contact details: Paul Little, pl@vesperbio.com, Scherfigsvej 7, 2100 Copenhagen, Denmark